

APPLICATIONS

European Pharmacopeia Monograph 2287 Fluconazole: Efficient Separation on Fully Porous and Core-Shell C18 Columns Within the Allowable Adjustments

Zeshan Aqeel¹, Dirk Hansen², and Heiko Behr²

¹Phenomenex, Inc., 411 Madrid Avenue, Torrance, CA 90501 USA

²Phenomenex Ltd. Deutschland, Zeppelinstraße 5, 63741 Aschaffenburg, Germany



Zeshan Aqeel
Senior Application Scientist
Zeshan loves to collect watches and the *Back to the Future* Trilogy. He has twin boys and a baby girl which drive him crazy! He is an Apple Fanboy for life and he likes being in the lab more than anywhere else.

Introduction

Fluconazole [2-(2,4-Difluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)propan-2-ol] is a triazole based systemic antifungal medication. It belongs to the first-generation antifungals used for oral treatment of Candida infections. The desirable pharmacologic properties of Fluconazole include a relatively long half-life, and the ability to be administered orally or parentally¹. The monograph for related substances of Fluconazole specifies three main impurities (A [2(RS)-2-(2,4-Difluorophenyl)-1-(1H-1,2,4-triazol-1-yl)-3-(4H-1,2,4-triazol-4-yl)propan-2-ol], B {2-[2-fluoro-4-(1H-1,2,4-triazol-1-yl)phenyl]-1,3-bis(1H-1,2,4-triazol-1-yl)propan-2-ol}, and C [1,1'-(1,3-phenylene)di-1H-1,2,4-triazole]) which need to be separated and detected to demonstrate compliance².

Conditions

LC-UV Conditions

Columns: Luna® 5 µm C18(2) 150 x 4.6 mm ([00F-4252-E0](#))
Kinetex® 2.6 µm C18 100 x 4.6 mm ([00D-4462-E0](#))

Mobile Phase: Isocratic (84:16)

A: 0.63 g/L Ammonium formate in water
B: Acetonitrile

Flow Rate: 1.0 mL/min

Temperature: 40 °C

Detection: UV @ 260 nm

Injection Volume: 20 µL

HPLC System: Agilent® 1260 (Agilent Technologies®, Santa Clara, CA, USA)

Table 1
Preparation of Test and Reference Solutions

| Solution | Step 1 | Step 2 | Step 3 | Final Conc. |
|---------------|---|-------------------------------------|--|---|
| Test Solution | 100 mg Fluconazole | dissolve in mobile phase | sonicate if necessary and dilute to 10.0 mL with mobile phase | 10 mg/mL Fluconazole |
| Ref a | dilute 5.0 mL Test Solution with mobile phase to 100.0 mL | take 1.0 mL | dilute with mobile phase to 10.0 mL | 0.05 mg/mL Fluconazole |
| Ref b | 5 mg Fluconazole for Peak Identification | dissolve in mobile phase | sonicate if necessary and dilute to 10.0 mL with mobile phase | 0.5 mg/mL Fluconazole |
| Ref c | 3.0 mg Fluconazole impurity B | dissolve in mobile phase | sonicate if necessary and dilute with mobile phase to 100.0 mL | 0.03 mg/mL impurity B |
| Ref d | 3.0 mg Fluconazole impurity C | dissolve in mobile phase | sonicate if necessary and dilute with mobile phase to 20.0 mL | 0.15 mg/mL impurity C |
| Ref e | 1.0 mL Ref d | add 1.0 mL Test Solution | dilute with mobile phase to 10.0 mL | 0.015 mg/mL impurity C 1 mg/mL Fluconazole |
| Ref f | 1.0 mL Ref d | dilute with mobile phase to 10.0 mL | | 0.015 mg/mL impurity C |

Results

The test solution and reference solutions (a) to (f) have been prepared as indicated in the monograph for Fluconazole² and detailed in **Table 1**. **Figures 2a** and **2b** show the chromatograms for the peak identification of the Fluconazole peak. The respective retention times achieved are 12.86 min on Luna 5 µm C18(2) and 5.12 min on Kinetex 2.6 µm C18. The peak identification of impurity A and Fluconazole is shown in **Figures 3a** and **3b**. The retention time for impurity A is 6.33 min on Luna 5 µm C18(2) and

2.71 min on Kinetex 2.6 µm C18. Impurity B is identified through injection of reference solution (c) shown in **Figures 4a** and **4b**. The retention time for this impurity is 5.58 min on Luna 5 µm C18(2) and 2.49 min on Kinetex 2.6 µm C18. The last impurity – impurity C – is identified through injection of reference solution (f) shown in **Figures 7a** and **7b**. The respective retention times for impurity C are 10.69 min on Luna 5 µm C18(2) and 8.34 min on Kinetex 2.6 µm C18.



Have questions or want more details on implementing this method? We would love to help!
Visit www.phenomenex.com/LiveChat to get in touch with one of our Technical Specialists

APPLICATIONS

Test and Reference solutions

Test solution

100 mg of Fluconazole was dissolved in mobile phase, sonicated and diluted to 10 mL with mobile phase – Injection: 20 µL

Figure 1a

Test Solution (10 mg/mL of Fluconazole CRS) on Luna® 5 µm C18(2)
150 x 4.6 mm





Figure 1b

Test Solution (10 mg/mL of Fluconazole CRS) on Kinetex® 2.6 µm C18
100 x 4.6 mm



| Peak No. | Analyte | Time | Area | Height | Width | Area% | Symmetry |
|----------|-------------|--------|---------|--------|--------|--------|----------|
| 1 | Impurity B | 5.579 | 74.2 | 9.3 | 0.1209 | 0.525 | 0.935 |
| 2 | Impurity A | 6.33 | 11 | 1.2 | 0.1408 | 0.078 | 0.841 |
| 3 | Fluconazole | 12.256 | 14052.7 | 506.8 | 0.3875 | 99.397 | 0.214 |


| Peak No. | Analyte | Time | Area | Height | Width | Area% | Symmetry |
|----------|-------------|-------|---------|--------|--------|--------|----------|
| 1 | Impurity B | 2.489 | 73.8 | 25.7 | 0.0456 | 0.521 | 0.814 |
| 2 | Impurity A | 2.703 | 11.3 | 3.4 | 0.0506 | 0.080 | 0.868 |
| 3 | Fluconazole | 4.744 | 14075.9 | 912.3 | 0.208 | 99.399 | 0.146 |

Reference solution (a)

5 mL of the test solution was diluted to 100 mL with the mobile phase. 1 mL of this solution was then diluted to 10 mL with the mobile phase – Injection: 20 µL.

Figure 2a


Reference solution (a) on Luna 5 µm C18(2) on Agilent® 1260



| Peak No. | Analyte | Time | Area | Height | Width | Area% | Symmetry |
|----------|-------------|-------|------|--------|--------|---------|----------|
| 1 | Fluconazole | 12.86 | 77.4 | 4.3 | 0.2719 | 100.000 | 0.93 |

Figure 2b

Reference solution (a) on Kinetex 2.6 µm C18 on Agilent 1260




| Peak No. | Analyte | Time | Area | Height | Width | Area% | Symmetry |
|----------|-------------|------|------|--------|--------|---------|----------|
| 1 | Fluconazole | 5.12 | 72.8 | 12.6 | 0.0915 | 100.000 | 0.812 |

Reference solution (b)


5mg of Fluconazole for peak identification CRS (containing impurity A) was dissolved in mobile phase, sonicated and diluted to 10mL with the mobile phase—Injection: 20µL.

Figure 3a

Reference solution (b) on Luna[®] 5 µm C18(2) on Agilent[®] 1260

**Figure 3b**

Reference solution (b) on Kinetex[®] 2.6 µm C18 on Agilent 1260



| Peak No. | Analyte | Time | Area | Height | Width | Area% | Symmetry |
|----------|-------------|--------|-------|--------|--------|--------|----------|
| 1 | Impurity A | 6.332 | 7.4 | 8.3E-1 | 0.1477 | 1.307 | 0.987 |
| 2 | Fluconazole | 12.826 | 558.4 | 32.7 | 0.2633 | 98.693 | 0.857 |


| Peak No. | Analyte | Time | Area | Height | Width | Area% | Symmetry |
|----------|-------------|-------|-------|--------|--------|--------|----------|
| 1 | Impurity A | 2.709 | 6.5 | 2.1 | 0.052 | 1.149 | 1.191 |
| 2 | Fluconazole | 5.088 | 558.5 | 94.2 | 0.0892 | 98.851 | 0.623 |

Reference solution (c)


3.0mg of Fluconazole impurity B CRS was dissolved in the mobile phase, sonicated and then diluted to 100mL with mobile phase—Injection: 20µL.

Figure 4a

Reference solution (c) on Luna 5 µm C18(2) on Agilent 1260

**Figure 4b**

Reference solution (c) on Kinetex 2.6 µm C18 on Agilent 1260



| Peak No. | Analyte | Time | Area | Height | Width | Area% | Symmetry |
|----------|------------|-------|-------|--------|--------|---------|----------|
| 1 | Impurity B | 5.582 | 458.8 | 57.4 | 0.1213 | 100.000 | 0.918 |

| Peak No. | Analyte | Time | Area | Height | Width | Area% | Symmetry |
|----------|------------|-------|-------|--------|--------|---------|----------|
| 1 | Impurity B | 2.493 | 457.7 | 143.3 | 0.0533 | 100.000 | 0.762 |



Have questions or want more details on implementing this method? We would love to help!
 Visit www.phenomenex.com/LiveChat to get in touch with one of our Technical Specialists


APPLICATIONS

Reference solution (d)

3.0 mg of Fluconazole impurity C CRS was dissolved in the mobile phase, sonicated and then diluted to 20 mL with mobile phase—Injection: 20 µL

Figure 5a


Reference solution (d) on Luna® 5 µm C18(2) on Agilent® 1260



| Peak No. | Analyte | Time | Area | Height | Width | Area% | Symmetry |
|----------|------------|--------|-------|--------|--------|---------|----------|
| 1 | Impurity C | 10.684 | 582.2 | 41.6 | 0.2153 | 100.000 | 0.935 |

Figure 5b

Reference solution (d) on Kinetex® 2.6 µm C18 on Agilent 1260




| Peak No. | Analyte | Time | Area | Height | Width | Area% | Symmetry |
|----------|------------|-------|-------|--------|--------|---------|----------|
| 1 | Impurity C | 4.418 | 580.3 | 115 | 0.0789 | 100.000 | 0.824 |

Reference solution (e)

System suitability: A mixture of 1 mL of reference solution (d) and 1 mL of test solution were diluted to 10 mL with the solvent mixture. Injection: 20 µL.

Figure 6a


Reference solution (e) on Luna 5 µm C18(2) on Agilent 1260



| Peak No. | Analyte | Time | Area | Height | Width | Area% | Symmetry |
|----------|-------------|--------|--------|--------|--------|--------|----------|
| 1 | Impurity C | 10.678 | 59.1 | 4.1 | 0.2227 | 3.998 | 0.932 |
| 2 | Fluconazole | 12.769 | 1418.5 | 81.4 | 0.2674 | 96.002 | 0.697 |

Figure 6b

Reference solution (e) on Kinetex 2.6 µm C18 on Agilent 1260



| Inj. | # | Analyte | Time | Area | Height | Width | Resolution |
|----------------|---|-------------|--------|--------|--------|-----------|------------|
| 1 | 1 | Impurity C | 10.678 | 59.1 | 4.1 | 0.2227 | 5.15 |
| | 2 | Fluconazole | 12.769 | 1418.5 | 81.4 | 0.2674 | |
| 2 | 1 | Impurity C | 10.695 | 59.7 | 4.1 | 0.2245 | 5.12 |
| | 2 | Fluconazole | 12.785 | 1416.7 | 81.3 | 0.2714 | |
| 3 | 1 | Impurity C | 10.68 | 58.2 | 4.1 | 0.2216 | 5.15 |
| | 2 | Fluconazole | 12.776 | 1415.2 | 81.2 | 0.2674 | |
| 4 | 1 | Impurity C | 10.683 | 58.8 | 4.1 | 0.2175 | 5.13 |
| | 2 | Fluconazole | 12.774 | 1413.7 | 81.3 | 0.2668 | |
| 5 | 1 | Impurity C | 10.695 | 62.1 | 4.2 | 0.23 | 5.11 |
| | 2 | Fluconazole | 12.785 | 1414.9 | 81.3 | 0.271 | |
| Average | | | | | | 5.132 | |
| STD | | | | | | 0.0178885 | |
| %RSD | | | | | | 0.3485687 | |

| Inj. | # | Analyte | Time | Area | Height | Width | Resolution |
|----------------|---|-------------|-------|--------|--------|-----------|------------|
| 1 | 1 | Impurity C | 4.411 | 58.6 | 11.6 | 0.0791 | 4.22 |
| | 2 | Fluconazole | 5.04 | 1414.2 | 210.8 | 0.0983 | |
| 2 | 1 | Impurity C | 4.413 | 58.7 | 11.5 | 0.0754 | 4.22 |
| | 2 | Fluconazole | 5.043 | 1411.7 | 204.2 | 0.1007 | |
| 3 | 1 | Impurity C | 4.413 | 56.2 | 11.6 | 0.0708 | 4.2 |
| | 2 | Fluconazole | 5.038 | 1409.3 | 209 | 0.0967 | |
| 4 | 1 | Impurity C | 4.413 | 56.4 | 11.7 | 0.0709 | 4.21 |
| | 2 | Fluconazole | 5.038 | 1406.2 | 209.1 | 0.0985 | |
| 5 | 1 | Impurity C | 4.414 | 56.6 | 11.7 | 0.0736 | 4.21 |
| | 2 | Fluconazole | 5.038 | 1408.5 | 209.3 | 0.0955 | |
| Average | | | | | | 4.212 | |
| STD | | | | | | 0.0083666 | |
| %RSD | | | | | | 0.1986372 | |


The Luna[®] 5 µm C18(2) column and the Kinetex[®] 2.6 µm C18 column were able to provide a resolution factor between Fluconazole and impurity C above the system suitability requirement of 3.0. The resolution on Luna 5 µm C18(2) was 5.13 (**Table 2**). The resolution on Kinetex 2.6 µm C18 was 4.21 (**Table 3**).

Reference solution (f)

A mixture of 1 mL of reference solution (d) was diluted to 10 mL with the mobile phase. Injection: 20 µL.

Figure 7a


Reference solution (f) on Luna 5 µm C18(2) on Agilent[®] 1260



| Peak No. | Analyte | Time | Area | Height | Width | Area% | Symmetry |
|----------|------------|--------|------|--------|-------|---------|----------|
| 1 | Impurity C | 10.687 | 62.3 | 4.2 | 0.224 | 100.000 | 0.914 |

Figure 7b

Reference solution (f) on Kinetex 2.6 µm C18 on Agilent 1260



| Analyte | Time | Area | Height | Width | Area% | Symmetry |
|------------|-------|------|--------|--------|---------|----------|
| Impurity C | 8.338 | 60.4 | 5 | 0.1842 | 100.000 | 0.837 |

Conclusion

The above experiments show both Luna 5 µm C18(2) and Kinetex 2.6 µm C18 are suitable under the conditions outlined in the monograph for Fluconazole². With the Kinetex 2.6 µm C18 column we demonstrated the possibility to reduce the total analysis time significantly by reducing the retention time for Fluconazole to 5.0 min within the allowable adjustments of compendial methods³. Therefore, Luna 5 µm C18(2) and Kinetex 2.6 µm C18 are reliable solutions for the analysis of Fluconazole in routine laboratories following the Ph. Eur. regulations.

References

- Wallace, J. E.; Harris, S. C.; Gallegos, J.; Foulds, G.; Chen, T. J. H.; Rinaldi, M. G., *Antimicrobial Agents and Chemotherapy*, 1992, 36(3), 603-606
- European Pharmacopoeia; Supplement 10 – Monograph 2287
- European Pharmacopoeia; Supplement 10 – Chapter 2.2.46 Chromatographic Separation Techniques

Sources of Standards

| Standard | Source |
|--|----------------|
| Fluconazole CRS | EDQM, Y0000557 |
| Fluconazole for Peak Identification CRS (contains Impurity A) | EDQM, Y0000558 |
| Fluconazole impurity B CRS | EDQM, Y0000573 |
| Fluconazole impurity C CRS | EDQM, Y0000574 |



Have questions or want more details on implementing this method? We would love to help!
Visit www.phenomenex.com/LiveChat to get in touch with one of our Technical Specialists

Ordering Information

Luna® 3 µm MidBore™ and Analytical Columns (mm)

| Phases | 30 x 3.0 | 50 x 3.0 | 150 x 3.0 | 30 x 4.6 | 50 x 4.6 | 75 x 4.6 | 100 x 4.6 | 150 x 4.6 | 4 x 2.0* | 4 x 3.0* |
|--------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|----------|----------|
| C18(2) | 00A-4251-Y0 | 00B-4251-Y0 | 00F-4251-Y0 | 00A-4251-E0 | 00B-4251-E0 | 00C-4251-E0 | 00D-4251-E0 | 00F-4251-E0 | /10pk | /10pk |

Luna® 5 µm MidBore and Analytical Columns (mm)

| Phases | 30 x 3.0 | 50 x 3.0 | 150 x 3.0 | 250 x 3.0 | 30 x 4.6 | 50 x 4.6 | 75 x 4.6 | 4 x 2.0* | 4 x 3.0* |
|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|----------|----------|
| Luna C18(2) | 00A-4252-Y0 | 00B-4252-Y0 | 00F-4252-Y0 | 00G-4252-Y0 | 00A-4252-E0 | 00B-4252-E0 | 00C-4252-E0 | /10pk | /10pk |

Luna® 5 µm Analytical and Semi-Prep Columns (mm)

| Phases | 100 x 4.6 | 150 x 4.6 | 250 x 4.6 | 250 x 10 | 4 x 3.0* | 10 x 10** |
|-------------|-------------|-------------|-------------|-------------|----------|-----------|
| Luna C18(2) | 00D-4252-E0 | 00F-4252-E0 | 00G-4252-E0 | 00G-4252-N0 | AJ0-4287 | AJ0-7221 |

for ID: 3.2-8.0 mm 9-16 mm

Kinetex® 2.6 µm Analytical Columns (mm)

| Phases | 30 x 4.6 | 50 x 4.6 | 75 x 4.6 | 100 x 4.6 | 150 x 4.6 | 250 x 4.6 | 3/pk |
|--------|-------------|-------------|-------------|-------------|-------------|-------------|----------|
| C18 | 00A-4462-E0 | 00B-4462-E0 | 00C-4462-E0 | 00D-4462-E0 | 00F-4462-E0 | 00G-4462-E0 | AJ0-8768 |

for 4.6 mm ID

† SecurityGuard ULTRA Cartridges require holder, Part No.: AJ0-9000

* SecurityGuard Analytical Cartridges require holder, Part No.: KJ0-4282

** SemiPREP SecurityGuard Cartridges require holder, Part No.: AJ0-9281



Your happiness is our mission. Take 45 days to try our products. If you are not happy, we'll make it right.
www.phenomenex.com/behappy

Australia
t: +61 (02) 9428-6444
auinfo@phenomenex.com

Austria
t: +43 (0) 1-319-1301
anfrage@phenomenex.com

Belgium
t: +32 (0)2 503 4015 (French)
t: +32 (0)2 511 8666 (Dutch)
beinfo@phenomenex.com

Canada
t: +1 (800) 543-3681
info@phenomenex.com

China
t: +86 400-606-8099
cninfo@phenomenex.com

Czech Republic
t: +420 272 017 077
cz-info@phenomenex.com

Denmark
t: +45 4824 8048
nordicinfo@phenomenex.com

Finland
t: +358 (0)9 4789 0063
nordicinfo@phenomenex.com

France
t: +33 (0)1 30 09 21 10
franceinfo@phenomenex.com

Germany
t: +49 (0)6021-58830-0
anfrage@phenomenex.com

India
t: +91 (0)40-3012 2400
indiainfo@phenomenex.com

Ireland
t: +353 (0)1 247 5405
eireinfo@phenomenex.com

Italy
t: +39 051 6327511
italiainfo@phenomenex.com

Luxembourg
t: +31 (0)30-2418700
nlinfo@phenomenex.com

Mexico
t: 01-800-844-5226
tecnicomx@phenomenex.com

The Netherlands
t: +31 (0)30-2418700
nlinfo@phenomenex.com

New Zealand
t: +64 (0)9-4780951
nzinfo@phenomenex.com

Norway
t: +47 810 02 005
nordicinfo@phenomenex.com

Poland
t: +48 22 104 21 72
pl-info@phenomenex.com

Portugal
t: +351 221 450 488
ptinfo@phenomenex.com

Singapore
t: +65 800-852-3944
sginfo@phenomenex.com

Slovakia
t: +420 272 017 077
sk-info@phenomenex.com

Spain
t: +34 91-413-8613
espinfo@phenomenex.com

Sweden
t: +46 (0)8 611 6950
nordicinfo@phenomenex.com

Switzerland
t: +41 (0)61 692 20 20
swissinfo@phenomenex.com

Taiwan
t: +866 (0) 0801-49-1246
twinfo@phenomenex.com

United Kingdom
t: +44 (0)1625-501367
ukinfo@phenomenex.com

USA
t: +1 (310) 212-0555
info@phenomenex.com

All other countries/regions
Corporate Office USA
t: +1 (310) 212-0555
info@phenomenex.com

Terms and Conditions
Subject to Phenomenex Standard Terms & Conditions, which may be viewed at www.phenomenex.com/TermsAndConditions.

Trademarks
Kinetex and Luna are registered trademarks and SecurityGuard and BE-HAPPY are trademarks of Phenomenex. Agilent is a registered trademark of Agilent Technologies, Inc.

Disclaimer
Comparative separations may not be representative of all applications. Phenomenex is not affiliated with Agilent Technologies, Inc.

FOR RESEARCH USE ONLY. Not for use in clinical diagnostic procedures.

© 2020 Phenomenex, Inc. All rights reserved.



www.phenomenex.com

Phenomenex products are available worldwide. For the distributor in your country/region, contact Phenomenex USA, International Department at international@phenomenex.com